DCM
VYGR icon

Driehaus Capital Management’s Voyager Therapeutics VYGR Stock Holding History

Driehaus Capital Management’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-19,752
Closed -$407K – 609
2017
Q3 		$407K Buy
+19,752
New +$223K 0.02% 415

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Driehaus Capital Management's VYGR Position: Q4 2017 in Review

Driehaus Capital Management sold out of Voyager Therapeutics (VYGR) in Q4 2017, closing a stake of 19,752 shares — an estimated $407K sold.

Driehaus Capital Management first reported a position in VYGR in Q3 2017 and held it in 1 quarter. The position peaked at $407K in Q3 2017. 98 funds tracked by Wall St. Rank hold VYGR as of Q4 2017.

  • Driehaus Capital Management reported no remaining Voyager Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Driehaus Capital Management sold 19,752 Voyager Therapeutics shares in Q4 2017, an estimated $407K.
  • Driehaus Capital Management first reported a position in Voyager Therapeutics in Q3 2017 and held it in 1 quarter.
  • Driehaus Capital Management's Voyager Therapeutics position peaked at $407K in Q3 2017.
  • 98 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q4 2017.

Based on Driehaus Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.